Kinase drug discovery remains a vital area in developing targeted therapies for diseases like cancer, inflammatory disorders, and more. Despite significant advances, challenges persist, including overcoming drug resistance, improving selectivity to minimize off-target effects, identifying novel kinase targets, and tailoring treatments to individual patients through personalized medicine. Additionally, expanding the use of kinase inhibitors to treat non-cancerous diseases opens new avenues for research and development. Addressing these unmet needs requires innovative approaches in drug design, a deeper understanding of disease mechanisms, and the integration of new technologies to refine clinical strategies, promising a future of more effective and precise treatments in kinase-targeted therapy.
Current progress in the field of KRAS drug discovery is a testament to the power of perseverance and innovation in pharmaceutical research. With ongoing clinical trials and the FDA approval of the first targeted KRAS G12C inhibitor, the landscape of cancer treatment is undergoing a significant transformation. Looking forward, the focus is not only on discovering more selective drugs that target different KRAS mutations but also on understanding the complex biology of KRAS inhibition to circumvent resistance mechanisms and improve patient outcomes. The era of direct KRAS targeting has just begun, and the potential for developing more effective cancer treatments is vast and inspiring.
Two prominent modalities within targeted protein degradation are PROTACs (Proteolysis Targeting Chimeras) and molecular glues. PROTACs function by recruiting an E3 ubiquitin ligase to a target protein, leading to its ubiquitination and subsequent degradation by the proteasome. This strategy enables the degradation of proteins considered "undruggable" by traditional small molecule inhibitors. On the other hand, molecular glues induce protein-protein interactions that result in the degradation of specific targets, providing an alternative approach to PROTACs.
From the initial stages of compound screening to the detailed analysis of drug efficacy and safety, our IVP services integrate seamlessly into the drug development pipeline. Our sophisticated CDX (Cell-Derived Xenograft) models, which include living image cell lines, drug-resistant variants, and gene-edited lines, are meticulously designed to reflect the human biological response to novel treatments. These models serve as critical platforms for testing and refining anti-tumor agents, ensuring that only the most promising candidates move forward in the drug discovery process.
Address: Bldg 16, Yd 18, Kechuang 13th St, Etown, Tongzhou Dist, Beijing, 100176, China
Email: marketing@ice-biosci.com
Tel：+86-10-67809840
